Study: Ultrasound, blood test miss early-stage ovarian cancer

A British study found that a combination of transvaginal ultrasound and CA-125 protein blood test is unlikely to spot ovarian cancer at an early stage. The study suggests that ovarian cancer screening should not be administered to women who are not at high risk of developing the disease, except those who are included in a trial designed to enhance screening techniques.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC